A venture capital firm founded in the USA closed its first fund in 2017 and is actively seeking new investment opportunities. The fund will make 15-20 investments in total with no set number of investments per year. The firm will be actively involved in their portfolio companies and will invest up to $25 million over the life of each portfolio company. Initial check sizes will depend on the company’s stage of development and their needs prior to investment. The firm will invest in North American or European companies.
The firm is focused solely on therapeutics and therapeutic platforms. The fund will invest at any stage of development from preclinical / discovery stage through Phase 3 clinical, and will invest in all therapeutic areas.
The firm can work with companies at all stages of their evolution. The firm’s team has the capability and experience to build companies from the ground up, however generally gets involved with at least the beginnings of a management team in place. The firm can both lead and co-invest along syndicates and will generally seek board representation in portfolio companies.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment